NCT07037238View on ClinicalTrials.gov

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Vascular Malformations
Interventions
DRUG

Everolimus 10mg daily

An oral mTOR inhibitor

Trial Locations (1)

Unknown

RECRUITING

the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Xuanwu Hospital, Beijing

OTHER